Vanta Bioscience share price
High risk
You have to be logged in to add this to Watchlist.- ₹27.32(1.94%)June 13, 2025 14:15:00 PM IST
- NSE
- BSE
- Vol : 0.75K (NSE + BSE)Last 20 day avg : 2.93 K
Vanta Bioscience is trading 1.94% upper at Rs 27.32 as compared to its last closing price. Vanta Bioscience has been trading in the price range of 27.32 & 27.32. Vanta Bioscience has given -39.69% in this year & 0.00% in the last 5 days. The company posted a net profit of -2.07 Crores in its last quarter.Listed peers of Vanta Bioscience include Norris Medicines (-4.45%), Aa Plus Tradelink (-%), Vanta Bioscience (1.94%).The Mutual Fund holding in Vanta Bioscience was at -% in . The MF holding has - from the last quarter. The FII holding in Vanta Bioscience was at -% in . The FII holding has - from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Key Metrics
Updated on Jun 13, 2025, 07:41 PM UTC
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/BLower than historical values1.11The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values0.00Price-to-earnings ratio based on trailing 12-month earnings
- BetaLow volatility0.21Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry4.01The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Vanta Bioscience Financials
Financials
View allFinancials include key reports like the Profit & Loss Statement (P&L), Balance Sheet, and Cash Flow Statement, providing insights into a company's performance, financial health, and liquidity
- Income
- Balance Sheet
- Cash Flow
Loading...
Units in the chart are in crores
Insights
- Financial
- Valuation
Company is not profitable- The debt to equity of the company is higher than the industry median
- Earnings are insufficient to cover the interest expenses on outstanding debt
Vanta Bioscience Technical Analysis
Pivot Level - classic
Key price levels (support and resistance) calculated using the previous day's high, low, and close, aiding in technical analysis and trading decisions
- R1
- 26.30
- R2
- 27.30
- R3
- 27.81
Pivot25.79
- S1
- 24.79
- S2
- 24.28
- S3
- 23.28
Short Term
Considers price movement over the last 1-2 weeks
Not Available
Long Term
Considers price movement over the last 6 months
Not Available
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Trends unavailable at the moment.
Vanta Bioscience Peers
Return Comparison
Peers Comparison
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Norris Medicines | Bearish | 18.02 | -4.45 | 18.16 | - | - | - | |
| Aa Plus Tradelink | Bearish | 0.81 | - | 19.70 | 19.97 | 0.44 | - | - |
| Vanta Bioscience | Neutral | 27.32 | 1.94 | 17.25 | - | 1.11 | - | 321.09 |
| Desh Rakshak Aushdhalaya | Bearish | 38.09 | - | 16.91 | 35.60 | 1.7 | - | 30.52 |
| Emmessar Biotech And Nutrition | Bearish | 32.85 | -0.18 | 16.42 | 54.84 | 2.17 | - | - |
Vanta Bioscience Shareholding
View AllShareholding Pattern
Breakdown of a company's ownership structure, showing stakes held by Promoters, Mutual Funds, FII(s) & Others.
Shareholding pattern for Vanta Bioscience is currently unavailable
Please check back later.
Shareholding Insights
Shareholding insights for Vanta Bioscience are currently unavailable
Please check back later.
Vanta Bioscience Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-30 | Audited Results |
| 2024-12-06 | Increase in Authorised Capital |
| 2024-11-14 | Half Yearly Results |
| 2024-07-19 | Audited Results |
| 2024-07-17 | Audited Results |
About the company Vanta Bioscience
- IndustryBiotechnology & Drugs
- ISININE695X01011
- BSE Code540729
- NSE Code
Vanta Bioscience Limited is an India-based preclinical contract research company. The Company provides services for testing and contract research in the fields of clinical research, pre-clinical research, biopharma services, analytical testing and research, and environmental studies. It offers a host of preclinical safety assessment services for clients from pharmaceuticals, medical devices, nutraceuticals, feed additives, biotech, agrochemicals, cosmetics, and chemical industries. Additionally, it provides risk assessment services to evaluate the safety of active pharmaceutical ingredients, excipients, extractables, leachable, and pharmaceutical impurities resulting from the manufacturing process or product degradation. The Company’s services include discovery toxicology, agro-chemical and chemical safety, biocompatibility studies, diet formulation, and batch release tests. The Company has investments in one of its subsidiaries, Vantaclinical Research Limited.
Vanta Bioscience Share Price FAQs
Vanta Bioscience is trading at 27.32 as on Fri Jun 13 2025 08:45:00. This is 1.94% upper as compared to its previous closing price of 26.80.
The market capitalization of Vanta Bioscience is 17.25 Cr as on Fri Jun 13 2025 08:45:00.
The 52 wk high for Vanta Bioscience is 64.84 whereas the 52 wk low is 19.08
Vanta Bioscience can be analyzed on the following key metrics -
- TTM P/E:
- Sector P/E: 72.15
- Dividend Yield: 0.00%
- D/E ratio: 4.83
Vanta Bioscience reported a net profit of -2.32 Cr in 2024.
Quick Links